Centers for Disease Control and Prevention Director Rochelle Walensky, M.D., late Friday authorized a third, additional dose of the mRNA COVID-19 vaccines for people with moderately to severely compromised immune systems. This includes people who have:

  • been receiving active cancer treatment for tumors or cancers of the blood;
  • received an organ transplant and are taking medicine to suppress the immune system;
  • received a stem cell transplant within the last two years or are taking medicine to suppress the immune system;
  • moderate or severe primary immunodeficiency (such as DiGeorge syndrome, Wiskott-Aldrich syndrome);
  • advanced or untreated HIV infection; and
  • are undergoing active treatment with high-dose corticosteroids or other drugs that may suppress your immune response.

CDC Tuesday, Aug. 17, at 2 p.m. ET will hold a call for clinicians to discuss additional doses, along with the current data on COVID-19 vaccines in immunocompromised people. Clinicians can follow this link to participate; a recording also will be available on the COCA Call webpage a few hours after the live event ends.
 

Related News Articles

Headline
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…
Headline
The AHA provided recommendations to the Food and Drug Administration Dec. 1 in response to a request for information on the measurement and evaluation of…
Headline
The Food and Drug Administration has identified a Class I recall of Baxter Life2000 Ventilation Systems due to a cybersecurity issue discovered through…
Headline
The Food and Drug Administration yesterday published an announcement from Otsuka ICU Medical saying that the company issued a voluntary recall for a mislabeled…
Headline
The Centers for Disease Control and Prevention will update its immunization schedules for the COVID-19 and chickenpox vaccines to adopt recent recommendations…
Headline
The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial…